Application and mechanism of angiotensin receptor-neprilysin inhibitor in early stage of acute myocardial infarction

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300074600

Enrollment

Unknown

Registered

2023-08-10

Start date

2021-11-01

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction

Interventions

Sacubitril/Valsartan group :50mg Sacubitril/Valsartan twice a day, and the dosage of Sacubitril/Valsartan should be adjusted once every 2 weeks according to the patient s blood pressure.

Valsartan group:Valsartan at the same frequency and dose

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients with type 1 acute myocardial infarction who have completed planned PCI and received treatment in accordance with international guidelines. (2) Patients aged from 18 to 80 (male or female); (3) The diagnostic criteria for type 1 acute myocardial infarction were consistent with the 2018 global uniform definition of fourth myocardial infarction; (4) NYHA cardiac function grade II-?

Exclusion criteria

Exclusion criteria: (1) Severe heart failure; (2) Blood pressure =90/60mmHg; (3) Had a stroke in the past three months; (4) Recurrent myocardial infarction; (5) Coronary artery bypass graft within the past 3 months or scheduled; (6) Had a tumour in the past 3 years; (7) neuromuscular disease or transient elevation of creatine kinase to more than 3 times the upper limit of the normal range (except for infarction); (8) Clinically significant non-transient hematological abnormalities; (9) Severe kidney disease with serum creatinine levels more than twice the upper limit of the normal range; (10) Severe liver disease; (11) A history of drug or alcohol abuse; (12) Currently or planning to receive systemic glucocorticoid therapy in the long term; (13) Clinically allergic to nohindal or currently using nohindal; (14) Refuse to participate in this study

Design outcomes

Primary

Measure	Time frame
Blood routine;hs-CRP;IL-6;IL-1ß;TNF-a;NT-proBNP;LVESD;LVEDD;LVEF;6 minute walk test;	—

Secondary

Measure	Time frame
all cause of death;death from cardiovascular causes;myocardial infarction;Stroke;	—

Countries

China

Contacts

Public Contactwang yong

The First People’s Hospital of Shangqiu

610577321@qq.com+86 182 7269 0952

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026